GIOTRIF® : The 1st choice in 1st-line

GIOTRIF® :
The 1st choice in 1st-line

Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
 
UNCOMMON EGFR MUTATIONS DATABASE Click here to access
 

GIOTRIF® followed by 3rd generation TKI in RESET study

Document ID: PC-MY-102638

26/10/2021

Author: Boehringer Ingelheim

123,000
Views

100k 340

RELATED CONTENT

 
PC-MY-102638
Production date: October 2021